20 June 2023 : Original article
Survival analysis of transplant-associated thrombotic microangiopathy under different diagnostic criteria and the efficacy of plasma exchange
Yifan Xu
12ABCDEF, Yan Wei12BF, Lijun Wang2BC, Ning Lu2BD, Yongli Wu2BD, Liping Dou2AF, Daihong Liu 2AF, Meng Li2ADEF*, Chunji Gao2ADEFG
DOI: 10.12659/AOT.939890
Ann Transplant 2023; 28:e939890
Table 1 Clinical characteristics of the TA-TMA.
| Characteristics | Total subjects (n=32) | PE (n=21) | Non-PE (n=11) | P value |
|---|---|---|---|---|
| 33.5 (13–61) | 34 (13–61) | 30 (15–61) | 0.690 | |
| 0.703 | ||||
| Male | 22 (68.8%) | 15 (71.4%) | 7 (63.6%) | |
| Female | 10 (31.2%) | 6 (28.6%) | 4 (36.4%) | |
| >0.99 | ||||
| AA | 2 (6.2%) | 1 (4.8%) | 1 (9.1%) | |
| MDS/AML/CML | 18 (56.3%) | 12 (57.1%) | 6 (54.5%) | |
| ALL | 12 (37.5%) | 8 (38.1%) | 4 (36.4%) | |
| >0.99 | ||||
| BU/CY+ATG | 29 (90.6%) | 19 (90.5%) | 10 (90.9%) | |
| FluCY-ATG | 1 (3.1%) | 1 (4.8%) | 0 (0.0%) | |
| TBI/CY/ATG | 2 (6.3%) | 1 (4.8%) | 1 (9.1%) | |
| 0.269 | ||||
| MUD | 4 (12.5%) | 4 (19.0%) | 0 (0.0%) | |
| Haplo | 26 (81.3%) | 15 (71.4%) | 11 (100.0%) | |
| MRD | 2 (6.2%) | 2 (9.5%) | 0 (0.0%) | |
| 0.283 | ||||
| Yes | 19 (59.4%) | 14 (66.7%) | 5 (45.5%) | |
| No | 13 (40.6%) | 7 (33.3%) | 6 (54.5%) | |
| >0.99 | ||||
| ABO mismatch | 9 (28.1%) | 6 (28.6%) | 3 (27.3%) | |
| ABO matched | 23 (71.9%) | 15 (71.4%) | 8 (72.7%) | |
| 0.071 | ||||
| HLA matched | 6 (18.8%) | 6 (28.6%) | 0 (0.0%) | |
| HLA mismatch | 26 (81.3%) | 15 (71.4%) | 11 (100.0%) | |
| 66.5 (22–591) | 91.0 (22–591) | 39.0 (29–234) | 0.005 | |
| TBIL (μmol/L), median | 12.9 (4.7–329.0) | 16.1 (4.7–329.0) | 11.3 (6.8–67.6) | 0.427 |
| PLT (×10/L), median | 22 (3–165) | 18 (3–165) | 28 (13–74) | 0.627 |
| Hb (g/L) | 69.7±13.2 | 66.7±13.4 | 75.4±11.4 | 0.013 |
| Schistocytes (%), median | 1.0 (0.0–4.0) | 1.5 (0.0–4.0) | 1.0 (0.0–1.2) | 0.157 |
| LDH (U/L), median | 355.0 (196.6–1790.4) | 380.0 (196.6–1790.4) | 336.2 (273.8–469.0) | 0.565 |
| 0.465 | ||||
| Yes | 12 (37.5%) | 9 (42.9%) | 3 (27.3%) | |
| No | 20 (62.5%) | 12 (57.1%) | 8 (72.7%) | |
| 0.072 | ||||
| Yes | 19 (59.4%) | 15 (71.4%) | 4 (36.3%) | |
| No | 13 (40.6%) | 6 (28.6%) | 7 (63.6%) | |
| 0.458 | ||||
| Yes | 21 (65.5%) | 12 (75.0%) | 9 (56.3%) | |
| No | 11 (34.4%) | 4 (25.0%) | 7 (43.8%) | |
| 0.465 | ||||
| Yes | 12 (37.5%) | 9 (42.9%) | 3 (27.3%) | |
| No | 20 (62.5%) | 12 (57.1%) | 8 (72.7%) | |
| 0.465 | ||||
| Yes | 14 (43.8%) | 8 (38.1%) | 6 (54.5%) | |
| No | 18 (56.3%) | 13 (61.9%) | 5 (45.5%) | |
| 0.123 | ||||
| Yes | 21 (65.6%) | 16 (76.2%) | 5 (45.5%) | |
| No | 11 (34.4%) | 5 (23.8%) | 6 (54.5%) | |
| >0.99 | ||||
| Yes | 31 (96.9%) | 20 (95.2%) | 1 1(100.0%) | |
| No | 1 (3.1%) | 1 (4.8%) | 0 (0.0%) | |
| Data are presented as the mean±SD, range (minimum-maximum), or n (%). HLA – human leukocyte antigen; AML – acute myeloblastic leukemia; ALL – acute lymphoblastic leukemia; CML – chronic myelogenous leukemia; MDS – myelodysplastic syndrome; AA – aplastic anemia; BU – busulfan; CY – cyclophosphamide; ATG – anti-thymocyte globulin; Flu – fludarabine; Haplo – haploidentical; MRD – matched related donor; MUD – matched unrelated donor. | ||||